Coronavirus Disease 2019 (COVID-19) vaccine 2 is under clinical development by Sinopharm Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Coronavirus Disease 2019 (COVID-19) vaccine 2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Coronavirus Disease 2019 (COVID-19) vaccine 2 overview
Coronavirus Disease 2019 (COVID-19 vaccine) is an inactivated vaccine composed of inactivated novel coronavirus antigen. It is formulated as solution for intramuscular route of administration. COVID-19 vaccine is indicated for the prevention of COVID-19 caused by the novel coronavirus.
Vaccine candidate is under development for prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a vero-cell-derived inactivated vaccine.
Sinopharm Group overview
Sinopharm Group (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp, distributes pharmaceutical and healthcare products. The company offers distribution, logistics, and other value-added services to pharmaceutical, medical, and healthcare product manufacturers and suppliers both domestically and internationally. It serves hospitals, primary health service institutions, and retail drug stores. Sinopharm also manufactures and sells pharmaceuticals, chemical reagents, laboratory supplies, and carries out the development of pharmaceuticals, medical services, and other health-related industries. The company manages a chain of medicine stores in China through direct operations and franchises to market pharmaceutical and healthcare products. Sinopharm is headquartered in Shanghai, China.
For a complete picture of Coronavirus Disease 2019 (COVID-19) vaccine 2’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
